{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T20:27:41Z","timestamp":1785616061489,"version":"3.56.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Cardiovascular Diseases"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.pcad.2025.10.002","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T22:19:23Z","timestamp":1760393963000},"page":"16-26","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Efficacy and safety of cardiac myosin inhibitors in obstructive hypertrophic cardiomyopathy: Systematic review and comprehensive frequentist and Bayesian meta-analyses of Phase 3 randomized controlled trials"],"prefix":"10.1016","volume":"94","author":[{"given":"Matthew M.Y.","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fraser C.","family":"Goldie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alasdair D.","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Masri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iacopo","family":"Olivotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline J.","family":"Coats","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"37","key":"10.1016\/j.pcad.2025.10.002_bb0005","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"2023 ESC guidelines for the management of cardiomyopathies","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur Heart J"},{"issue":"23","key":"10.1016\/j.pcad.2025.10.002_bb0010","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1016\/j.jacc.2024.02.014","article-title":"2024 AHA\/ACC\/AMSSM\/HRS\/PACES\/SCMR guideline for the management of hypertrophic cardiomyopathy","volume":"83","author":"Ommen","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.pcad.2025.10.002_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2022.101429","article-title":"Mavacamten treatment for hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomized controlled trials","volume":"48","author":"Ismayl","year":"2023","journal-title":"Curr Probl Cardiol"},{"issue":"1","key":"10.1016\/j.pcad.2025.10.002_bb0020","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s43044-023-00328-7","article-title":"Safety and efficacy of mavacamten for treatment of hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomized clinical trials","volume":"75","author":"Rabiee Rad","year":"2023","journal-title":"Egypt Heart J"},{"issue":"10","key":"10.1016\/j.pcad.2025.10.002_bb0025","doi-asserted-by":"crossref","DOI":"10.2144\/fsoa-2023-0059","article-title":"Efficacy and safety of mavacamten in treatment of hypertrophic cardiomyopathy: a systematic review and meta-analysis","volume":"9","author":"Memon","year":"2023","journal-title":"Future Sci OA"},{"issue":"1","key":"10.1016\/j.pcad.2025.10.002_bb0030","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s43044-023-00427-5","article-title":"Analyzing safety and effectiveness of Mavacamten in comparison with placebo for managing hypertrophic cardiomyopathy: a systemic review and meta-analysis","volume":"75","author":"Rangwala","year":"2023","journal-title":"Egypt Heart J"},{"issue":"2","key":"10.1016\/j.pcad.2025.10.002_bb0035","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10741-023-10375-6","article-title":"A systematic review and meta-analysis of the efficacy and safety of Mavacamten therapy in international cohort of 524 patients with hypertrophic cardiomyopathy","volume":"29","author":"Yacoub","year":"2024","journal-title":"Heart Fail Rev"},{"issue":"4","key":"10.1016\/j.pcad.2025.10.002_bb0040","doi-asserted-by":"crossref","first-page":"e491","DOI":"10.1097\/MJT.0000000000001698","article-title":"Effects of Mavacamten concomitant with beta-blockers on patients with hypertrophic cardiomyopathy: a meta-analysis of randomized controlled trials","volume":"31","author":"Rehan","year":"2024","journal-title":"Am J Ther"},{"issue":"4","key":"10.1016\/j.pcad.2025.10.002_bb0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0301704","article-title":"Evaluating the efficacy and safety of mavacamten in hypertrophic cardiomyopathy: a systematic review and meta-analysis focusing on qualitative assessment, biomarkers, and cardiac imaging","volume":"19","author":"Vyas","year":"2024","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.pcad.2025.10.002_bb0050","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2459\/JCM.0000000000001638","article-title":"Evaluation of mavacamten in patients with hypertrophic cardiomyopathy","volume":"25","author":"Liao","year":"2024","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"10.1016\/j.pcad.2025.10.002_bb0055","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.amjcard.2024.07.007","article-title":"Comparison of drug therapy efficacy in patients with hypertrophic cardiomyopathy: a network meta-analysis","volume":"226","author":"Shang","year":"2024","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pcad.2025.10.002_bb0060","article-title":"Efficacy and safety of Mavacamten for symptomatic hypertrophic cardiomyopathy - an updated meta-analysis of randomized controlled trials","volume":"53","author":"Ullah","year":"2024","journal-title":"Int J Cardiol Heart Vasc"},{"issue":"10","key":"10.1016\/j.pcad.2025.10.002_bb0065","doi-asserted-by":"crossref","first-page":"6097","DOI":"10.1097\/MS9.0000000000002466","article-title":"Efficacy and safety of mavacamten for the treatment of hypertrophic cardiomyopathy: an updated systematic review and meta-analysis of randomized controlled trials","volume":"86","author":"Almansouri","year":"2024","journal-title":"Ann Med Surg (Lond)"},{"issue":"10","key":"10.1016\/j.pcad.2025.10.002_bb0070","doi-asserted-by":"crossref","first-page":"375","DOI":"10.31083\/j.rcm2510375","article-title":"A systematic review and meta-analysis of efficacy and safety of Mavacamten for the treatment of hypertrophic cardiomyopathy","volume":"25","author":"Zheng","year":"2024","journal-title":"Rev Cardiovasc Med"},{"key":"10.1016\/j.pcad.2025.10.002_bb0075","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.amjcard.2023.10.059","article-title":"The efficacy of cardiac myosin inhibitors versus placebo in patients with symptomatic hypertrophic cardiomyopathy: a meta-analysis and systematic review","volume":"210","author":"Yassen","year":"2024","journal-title":"Am J Cardiol"},{"issue":"3","key":"10.1016\/j.pcad.2025.10.002_bb0080","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s40256-024-00710-z","article-title":"Cardiac myosin inhibitors for obstructive hypertrophic cardiomyopathy: a meta-analysis of randomized placebo-controlled trials","volume":"25","author":"Felix","year":"2025","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.pcad.2025.10.002_bb0085","doi-asserted-by":"crossref","DOI":"10.1097\/CRD.0000000000000803","article-title":"Efficacy and safety of cardiac myosin inhibitors in hypertrophic cardiomyopathy: a meta-analysis of randomized controlled trials","author":"Ahsan","year":"2024","journal-title":"Cardiol Rev"},{"key":"10.1016\/j.pcad.2025.10.002_bb0090","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.amjcard.2025.01.016","article-title":"The efficacy and safety of cardiac myosin inhibitors versus placebo in patients with symptomatic obstructive hypertrophic cardiomyopathy: a meta-analysis of randomized controlled trials","volume":"241","author":"Ezenna","year":"2025","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pcad.2025.10.002_bb0095","article-title":"Efficacy and safety of cardiac myosin inhibitors for symptomatic hypertrophic cardiomyopathy: a meta-analysis of randomized controlled trials","volume":"11","author":"Abunada","year":"2024","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"10.1016\/j.pcad.2025.10.002_bb0100","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2025-003215","article-title":"Efficacy of cardiac myosin inhibitors mavacamten and aficamten in hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomised controlled trials","volume":"12","author":"Aman","year":"2025","journal-title":"Open Heart"},{"issue":"15","key":"10.1016\/j.pcad.2025.10.002_bb0105","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/j.jacc.2025.03.139","article-title":"TCTAP A-093 Role of cardiac myosin inhibitors in the treatment of hypertrophic cardiomyopathy: an updated systematic review and meta-analysis of randomized controlled trials","volume":"85","author":"Almansouri","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.pcad.2025.10.002_bb0110","doi-asserted-by":"crossref","first-page":"3810","DOI":"10.1097\/MS9.0000000000003326","article-title":"Cardiac myosin inhibitors for hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomized controlled trials","volume":"87","author":"Hasana","year":"2025","journal-title":"Ann Med Surg"},{"issue":"5","key":"10.1016\/j.pcad.2025.10.002_bb0115","article-title":"B-27 | Efficacy and safety of cardiac myosin inhibitors in patient with symptomatic hypertrophic cardiomyopathy: an updated meta-analysis of randomized placebo-controlled trials","volume":"4","author":"Caputi","year":"2025","journal-title":"J Soc Cardiovasc Angiogr Interv"},{"issue":"5","key":"10.1016\/j.pcad.2025.10.002_bb0120","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/ehjcvp\/pvaf036","article-title":"Efficacy of pharmacological therapies in reducing outflow tract obstruction in patients with obstructive hypertrophic cardiomyopathy: a systematic review and meta-analysis","volume":"11","author":"Awad","year":"2025","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"24","key":"10.1016\/j.pcad.2025.10.002_bb0125","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1002\/sim.1009","article-title":"A refined method for the meta-analysis of controlled clinical trials with binary outcome","volume":"20","author":"Hartung","year":"2001","journal-title":"Stat Med"},{"key":"10.1016\/j.pcad.2025.10.002_bb0130","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1471-2288-14-25","article-title":"The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method","volume":"14","author":"IntHout","year":"2014","journal-title":"BMC Med Res Methodol"},{"issue":"3","key":"10.1016\/j.pcad.2025.10.002_bb0135","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/jrsm.1297","article-title":"Methods for evidence synthesis in the case of very few studies","volume":"9","author":"Bender","year":"2018","journal-title":"Res Synth Methods"},{"issue":"3","key":"10.1016\/j.pcad.2025.10.002_bb0140","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/cdev.12169","article-title":"A gentle introduction to Bayesian analysis: applications to developmental research","volume":"85","author":"van de Schoot","year":"2014","journal-title":"Child Dev"},{"issue":"4","key":"10.1016\/j.pcad.2025.10.002_bb0145","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/jrsm.1475","article-title":"On weakly informative prior distributions for the heterogeneity parameter in Bayesian random-effects meta-analysis","volume":"12","author":"R\u00f6ver","year":"2021","journal-title":"Res Synth Methods"},{"issue":"1","key":"10.1016\/j.pcad.2025.10.002_bb0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v080.i01","article-title":"brms: an R package for Bayesian multilevel models using Stan","volume":"80","author":"B\u00fcrkner","year":"2017","journal-title":"J Stat Softw"},{"key":"10.1016\/j.pcad.2025.10.002_bb0155","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"10253","key":"10.1016\/j.pcad.2025.10.002_bb0160","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.pcad.2025.10.002_bb0165","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jacc.2022.04.048","article-title":"Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy","volume":"80","author":"Desai","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.pcad.2025.10.002_bb0170","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1001\/jamacardio.2023.3030","article-title":"Effect of Mavacamten on Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy: the EXPLORER-CN randomized clinical trial","volume":"8","author":"Tian","year":"2023","journal-title":"JAMA Cardiol"},{"issue":"20","key":"10.1016\/j.pcad.2025.10.002_bb0175","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1056\/NEJMoa2401424","article-title":"Aficamten for symptomatic obstructive hypertrophic cardiomyopathy","volume":"390","author":"Maron","year":"2024","journal-title":"N Engl J Med"},{"issue":"10293","key":"10.1016\/j.pcad.2025.10.002_bb0180","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1016\/S0140-6736(21)00763-7","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"397","author":"Spertus","year":"2021","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.pcad.2025.10.002_bb0185","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/j.jacc.2024.08.014","article-title":"Effect of Aficamten on health status outcomes in obstructive hypertrophic cardiomyopathy: results from SEQUOIA-HCM","volume":"84","author":"Sherrod","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.pcad.2025.10.002_bb0190","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1001\/jamacardio.2022.5099","article-title":"Effects of Mavacamten on measures of cardiopulmonary exercise testing beyond peak oxygen consumption: a secondary analysis of the EXPLORER-HCM randomized trial","volume":"8","author":"Wheeler","year":"2023","journal-title":"JAMA Cardiol"},{"issue":"11","key":"10.1016\/j.pcad.2025.10.002_bb0195","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1001\/jamacardio.2024.2781","article-title":"Aficamten and cardiopulmonary exercise test performance: a substudy of the SEQUOIA-HCM randomized clinical trial","volume":"9","author":"Lee","year":"2024","journal-title":"JAMA Cardiol"},{"issue":"42","key":"10.1016\/j.pcad.2025.10.002_bb0200","doi-asserted-by":"crossref","first-page":"4464","DOI":"10.1093\/eurheartj\/ehae590","article-title":"Cardiac biomarkers and effects of aficamten in obstructive hypertrophic cardiomyopathy: the SEQUOIA-HCM trial","volume":"45","author":"Coats","year":"2024","journal-title":"Eur Heart J"},{"issue":"25","key":"10.1016\/j.pcad.2025.10.002_bb0205","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1016\/j.jacc.2021.09.1381","article-title":"Effect of Mavacamten on echocardiographic features in symptomatic patients with obstructive hypertrophic cardiomyopathy","volume":"78","author":"Hegde","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"19","key":"10.1016\/j.pcad.2025.10.002_bb0210","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/j.jacc.2024.08.002","article-title":"Impact of Aficamten on echocardiographic cardiac structure and function in symptomatic obstructive hypertrophic cardiomyopathy","volume":"84","author":"Hegde","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.pcad.2025.10.002_bb0215","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1161\/CIRCULATIONAHA.120.052359","article-title":"Mavacamten favorably impacts cardiac structure in obstructive hypertrophic cardiomyopathy: EXPLORER-HCM cardiac magnetic resonance substudy analysis","volume":"143","author":"Saberi","year":"2021","journal-title":"Circulation"},{"issue":"19","key":"10.1016\/j.pcad.2025.10.002_bb0220","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1016\/j.jacc.2024.08.015","article-title":"Effect of Aficamten on cardiac structure and function in obstructive hypertrophic cardiomyopathy: SEQUOIA-HCM CMR substudy","volume":"84","author":"Masri","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"15","key":"10.1016\/j.pcad.2025.10.002_bb0225","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.124.035993","article-title":"Dosing and safety profile of Aficamten in symptomatic obstructive hypertrophic cardiomyopathy: results from SEQUOIA-HCM","volume":"13","author":"Coats","year":"2024","journal-title":"J Am Heart Assoc"},{"issue":"19","key":"10.1016\/j.pcad.2025.10.002_bb0230","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1016\/j.jacc.2024.09.003","article-title":"Impact of Aficamten on disease and symptom burden in obstructive hypertrophic cardiomyopathy: results from SEQUOIA-HCM","volume":"84","author":"Maron","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.pcad.2025.10.002_bb0235","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/13696998.2021.2011301","article-title":"Assessing health-related quality-of-life in patients with symptomatic obstructive hypertrophic cardiomyopathy: EQ-5D-based utilities in the EXPLORER-HCM trial","volume":"25","author":"Xie","year":"2022","journal-title":"J Med Econ"},{"issue":"12","key":"10.1016\/j.pcad.2025.10.002_bb0240","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.122.014986","article-title":"Myosin inhibition and left ventricular diastolic function in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy: insights from the VALOR-HCM study","volume":"15","author":"Cremer","year":"2022","journal-title":"Circ Cardiovasc Imaging"},{"issue":"10","key":"10.1016\/j.pcad.2025.10.002_bb0245","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1001\/jamacardio.2023.3342","article-title":"Mavacamten in patients with hypertrophic cardiomyopathy referred for septal reduction: week 56 results from the VALOR-HCM randomized clinical trial","volume":"8","author":"Desai","year":"2023","journal-title":"JAMA Cardiol"},{"issue":"9","key":"10.1016\/j.pcad.2025.10.002_bb0250","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.124.017185","article-title":"Serial changes in ventricular strain in symptomatic obstructive hypertrophic cardiomyopathy treated with Mavacamten: insights from the VALOR-HCM trial","volume":"17","author":"Desai","year":"2024","journal-title":"Circ Cardiovasc Imaging"},{"issue":"3","key":"10.1016\/j.pcad.2025.10.002_bb0255","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jcmg.2024.08.005","article-title":"Mavacamten-associated temporal changes in left atrial function in obstructive HCM: insights from the VALOR-HCM trial","volume":"18","author":"Desai","year":"2025","journal-title":"JACC Cardiovasc Imaging"},{"issue":"11","key":"10.1016\/j.pcad.2025.10.002_bb0260","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.jacc.2024.06.025","article-title":"Mavacamten in obstructive hypertrophic cardiomyopathy patients referred for septal reduction: health status analysis through week 56 in VALOR-HCM trial","volume":"84","author":"Desai","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.pcad.2025.10.002_bb0265","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/s44161-024-00505-0","article-title":"Aficamten is a small-molecule cardiac myosin inhibitor designed to treat hypertrophic cardiomyopathy","volume":"3","author":"Hartman","year":"2024","journal-title":"Nat Cardiovasc Res"},{"issue":"21","key":"10.1016\/j.pcad.2025.10.002_bb0270","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1016\/j.jacc.2020.03.064","article-title":"Evaluation of Mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy","volume":"75","author":"Ho","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.pcad.2025.10.002_bb0275","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1056\/NEJMoa2505927","article-title":"Mavacamten in symptomatic nonobstructive hypertrophic cardiomyopathy","volume":"393","author":"Desai","year":"2025","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.pcad.2025.10.002_bb0280","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1056\/NEJMoa2504654","article-title":"Aficamten or metoprolol monotherapy for obstructive hypertrophic cardiomyopathy","volume":"393","author":"Garcia-Pavia","year":"2025","journal-title":"N Engl J Med"}],"container-title":["Progress in Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062025001483?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062025001483?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T20:14:51Z","timestamp":1773951291000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033062025001483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":56,"alternative-id":["S0033062025001483"],"URL":"https:\/\/doi.org\/10.1016\/j.pcad.2025.10.002","relation":{},"ISSN":["0033-0620"],"issn-type":[{"value":"0033-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of cardiac myosin inhibitors in obstructive hypertrophic cardiomyopathy: Systematic review and comprehensive frequentist and Bayesian meta-analyses of Phase 3 randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"Progress in Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcad.2025.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}